Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the <scp>HGB</scp> ‐206 study-Reference-Cited by-同舟云学术

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB ‐206 study

Published:2022-10-10 Issue:1 Volume:98 Page:11-22
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Kanter Julie¹^ORCID,Thompson Alexis A.²³,Pierciey Francis J.⁴,Hsieh Matthew⁵,Uchida Naoya⁵,Leboulch Philippe⁶⁷,Schmidt Manfred⁸,Bonner Melissa⁴,Guo Ruiting⁴,Miller Alex⁴,Ribeil Jean‐Antoine⁴,Davidson David⁴,Asmal Mohammed⁴,Walters Mark C.⁹^ORCID,Tisdale John F.⁵

Affiliation:

1. Department of Hematology‐Oncology University of Alabama Birmingham Birmingham Alabama USA

2. Division of Hematology, Oncology, and Stem Cell Transplantation Northwestern University Feinberg School of Medicine Chicago Illinois USA

3. Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA

4. bluebird bio, Inc. Somerville Massachusetts USA

5. Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute/National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda Maryland USA

6. Commissariat à l'énergie atomique et aux énergies alternatives, Institute of Emerging Disease and Innovative Therapies Fontenay‐aux‐Roses France

7. Department of Medicine Brigham & Women's Hospital and Harvard Medical School Boston Massachusetts USA

8. GeneWerk GmbH Heidelberg Germany

9. Division of Hematology University of California San Francisco Benioff Children's Hospital Oakland California USA

Funder

bluebird bio

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26741

Reference36 articles.

1. Sickle cell disease

2. Pathophysiology of Sickle Cell Disease

3. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease

4. Hydroxyurea increases fetal hemoglobin production in sickle cell anemia;Platt OS;Trans Assoc Am Phys,1984

5. BradtPS E. Synnott P. Chapman R. Rind D.M.;Pearson S.Crizanlizumab Voxelotor and L‐glutamine for sickle cell disease: effectiveness and value. Institute for Clinical and Economic Review;2020.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease;Antioxidants & Redox Signaling;2024-01-23

2. A new frontier: FDA approvals for gene therapy in sickle cell disease;Molecular Therapy;2024-01

3. An α-chain modification rivals the effect of fetal hemoglobin in retarding the rate of sickle cell fiber formation;Scientific Reports;2023-12-11

4. Gene therapy for sickle cell disease;Hematology;2023-12-08

5. Prostaglandin E2 as transduction enhancer affects competitive engraftment of human hematopoietic stem and progenitor cells;Molecular Therapy - Methods & Clinical Development;2023-12